Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

ABOS·NASDAQ

$2.37

+2.6%
HealthcareBiotechnology

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

At a Glance

Live Snapshot
Market Cap$143.26M
EPS-2.0000
P/E Ratio-1.18
Earnings Date08/11/2026

abos

Operating Expenses

Last Annual Value

123.83M

3-Year CAGR

40%

5-Year CAGR

147%

10-Year CAGR

29%

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. Competitors Analysis of Operating Expenses

ABOS · NASDAQ
CompanyOperating Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
123.83M
26.5%76.3%N/A 
SEER logo
Seer, Inc.
NASDAQ:SEER
86.46M
-6.7%3.9%N/A
22.50M
-3.4%N/AN/A
132.46M
-4.5%0.7%N/A
PEPG logo
PepGen Inc.
NASDAQ:PEPG
92.22M
3.3%27.7%N/A
52.37M
-31.0%-19.6%N/A
53.16M
84.5%63.0%N/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
123.73M
16.5%7.1%14.1%
56.46M
-1.5%24.3%12.2%
ALEC logo
Alector, Inc.
NASDAQ:ALEC
157.19M
-13.2%23.4%26.0%
86.89M
-15.6%-22.1%-2.6%
Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. Fair Value Envelope

ABOS · NASDAQ

Our analysis suggests that ABOS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.365, this represents a potential HIDDEN relative to our calculated worth for Acumen Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $2.365